Heart Failure
ESC 2022: Initiating Gliflozin in HFpEF During Hospitalization Can Benefit the Patient. This is Also Evidenced by Experience from the USA
Based on evidence from clinical studies, gliflozins are currently being introduced into…
Benefit of Adding Empagliflozin to Standard Therapy in Heart Failure with Reduced Ejection Fraction
The use of empagliflozin led to a reduction in the risk of hospitalization for heart failure…
Increase in Hematocrit During Empagliflozin Treatment in a Diabetic Patient with Severe Anemia − A Case Study
In a case study involving a 78-year-old diabetic patient, where only the administration of…
Influence of ARNI on the Efficacy and Safety of Empagliflozin in the Treatment of Heart Failure with Reduced Ejection Fraction
Pharmacological inhibition of neprilysin and the AT1 receptor for angiotensin II (ARNI)…
Summary of New American Recommendations for Heart Failure Management
This year, the American Heart Association (AHA), the American College of Cardiology (ACC), and…
Does empagliflozin improve the overall health of patients with heart failure with reduced LVEF?
A recently published secondary analysis of the EMPEROR-Reduced study is based mainly on the…
Empagliflozin Secures Reimbursement for Heart Failure Treatment
Starting May 1st, health insurance companies will cover Jardiance® (empagliflozin) for…
Efficacy and Safety of Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction
Previous studies have shown that the antidiabetic drug empagliflozin reduces the risk of…
Gliflozins Successfully Treat Type 2 Diabetes Mellitus and Heart Failure
The number of patients with type 2 diabetes mellitus (DM2) and heart failure is increasing…
EMA Approved Empagliflozin for the Treatment of Heart Failure Regardless of Left Ventricular Ejection Fraction
Prague, March 8, 2022 – Hundreds of thousands of patients in the Czech Republic can soon look…
Does gliflozin treatment for heart failure have greater benefits in diabetics?
Inhibitors of glucose reabsorption in the proximal tubule are represented on the domestic…
Proposal of a New Treatment Sequence Algorithm for Heart Failure with Reduced Ejection Fraction
John McMurray and Milton Packer published a proposal for a new treatment sequence algorithm…
Reverse Remodeling of LV in Patients with Diabetes/Prediabetes and Heart Failure with Reduced Ejection Fraction Treated with Empagliflozin
Authors of the British study SUGAR-DM-HF published in February 2021 examined whether…
Empagliflozin in the Treatment of Patients with Chronic Heart Failure
Unlike other antidiabetics, sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk…
Reduction of Risk of Hospitalizations for Heart Failure in Type 2 Diabetics
The EMPA-REG OUTCOME study already in 2015 highlighted one of the benefits of the…
Subscribe
E-courses on this topic
Conferences news
Go to records
Most read on this topic
- Empagliflozin Secures Reimbursement for Heart Failure Treatment
- Empagliflozin will be funded from May for symptomatic heart failure regardless of EF LK value
- Cardio-renal-metabolic syndrome in context
- Current Recommendations for Using SGLT2 Inhibitors in Patients with Renal or Cardiovascular Risk
Journal on this topic
Related topic